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Abstract: Increasing bone mineralization abnormalities observed among people living with 
HIV (PLWHIV) result from various factors relating to the host, the virus, and the antiretro-
virals used. Today, HIV infection is considered to be a risk factor for bone mineralization 
disorders. The test most recommended for diagnosing osteoporosis is measurement of bone 
mineral density by means of dual energy X-ray absorptiometry at two sites. Osteoporosis treat-
ment has the aims of bone mass improvement and fracture control. A combination of calcium 
and vitamin D supplementation may reduce the risk of fractures. Antiresorptive drugs act by 
blocking osteoclastic activity and reducing bone remodeling. On the other hand, bone-forming 
drugs stimulate osteoblastogenesis, thereby stimulating the formation of bone matrix. Mixed-
action medications are those that are capable of both stimulating bone formation and inhibiting 
reabsorption. Antiresorptive drugs form the group of medications with the greatest quantity of 
scientific evidence confirming their efficacy in osteoporosis treatment. Physical activity is a 
health promotion strategy for the general population, but only preliminary data on its real value 
and benefit among PLWHIV are available, especially in relation to osteoporosis.
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Introduction
Life expectancy has increased significantly among people living with HIV (PLWHIV) 
since the introduction of highly active antiretroviral therapy (HAART). Living with this 
viral infection for prolonged periods, and with its treatment, has certain consequences. 
For example, osteoarticular abnormalities are increasingly observed among such patients 
and are being studied in greater detail with the aim of detecting their possible causes and 
determining the most appropriate therapeutic approach. Among these complex changes, 
diminished bone mineralization is observed in a large percentage of the patients, resulting 
from various factors relating to the host, the virus, and the antiretrovirals used. Bone 
is constantly remodeled through synchronism between its formation and reabsorption, 
but this may become deregulated through HIV infection. When bone mineralization 
decreases, osteopenia occurs and may progress to osteoporosis.1
According to the World Health Organization, the definitions of osteopenia and 
osteoporosis are based on results from bone densitometry, in which the patient’s bone 
density is compared with the average for young adults, after adjusting for race and 
gender.2 The condition is defined as osteoporosis when the resulting relationship is 
below –2.5 times the standard deviation, and as osteopenia when the result is between 
–2.5 and –1.0 times the standard deviation.3 Patients should also be considered to pres-
ent osteoporosis if fragility fractures occur, caused by minimal trauma.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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HIV and bone metabolism
Many authors have shown that PLWHIV have a high preva-
lence of these abnormalities, according to the criteria cited 
above.3–11 Currently, HIV infection is considered to be a 
risk factor for bone mineralization disorders, and therefore 
it should be recommended that all postmenopausal HIV-
positive women and all HIV-positive men aged 49 years and 
over should be investigated for such disorders.12
Many factors have been reported to cause osteopenia in 
PLWHIV . Among these are direct effects from the virus on 
osteogenic cells; persistent activation of pro-inflammatory 
cytokines, especially tumor necrosis factor alpha (TNFα) 
and interleukin-1; changes to vitamin D metabolism, with 
deficiency of 1,25 dihydroxyvitamin D; and participation of 
mitochondrial abnormalities relating to lactic acidemia and 
the development of opportunistic diseases.5–7
Studies on the influence of antiretroviral treatment show 
that the relative risk is greater when protease inhibitors are 
used. Studies have also shown that indinavir inhibits bone 
formation and ritonavir inhibits osteoclast differentiation 
and function.2,6–9,13 Other factors may contribute towards 
accelerating the bone loss, such as nutritional deficiencies, 
low serum calcium levels, immobilization, hypogonadism, 
  hyperthyroidism, hyperparathyroidism, kidney failure, opioid 
or heroin use, corticosteroid use, postmenopausal status among 
women, and alcohol intake greater than 16 g/day.2,6,7,10–12
The most important risk factors associated with bone 
loss in HIV-positive patients are advanced age, smoking, 
  Caucasian race, low weight, and low body mass index (BMI). 
These risk factors, in this order of frequency (highest to 
  lowest), are the ones most commonly cited in studies, even 
in cases of long-duration infection.14
In a meta-analysis on ten studies, Bolland et al15 compared 
the impact of BMI on bone loss in HIV patients undergoing 
antiretroviral treatment. They concluded that the main factor 
that explained the difference in bone mineral density (BMD) 
between infected and normal individuals was low BMI. 
Special attention needs to be paid to alcohol consumption, 
which favors lactic acidosis, particularly among patients 
with hepatitis virus coinfection. Other factors that increase 
the risk of bone loss among PLWHIV include malnutrition; 
excessive weight loss; phosphocalcium disorders such as 
hypovitaminosis D; and hypogonadism, which is found in 
20% to 30% of HIV-positive men.16,17
HIV infection also modifies bone metabolism through 
several inflammatory factors, ie, direct effects of the virus 
on bone cells.18 HIV-positive patients have very high levels 
of anti-TNFα. The pro-inflammatory cytokines secreted by 
the T lymphocytes of HIV-positive patients affect their bone 
metabolism through inhibiting osteoblasts and   activating 
osteoclasts, and one of the mediators of these effects is 
the RANK-L (receptor activator of NF-kappaB – ligand) 
signaling pathway.19 The role of HIV in RANK-L activa-
tion (described in 2005) shows that people living with HIV 
have very high levels of RANK-L. TNFα may be implicated 
in inhibition of 1-α hydroxylase, which in turn alters the 
metabolism of vitamin D.20 Table 1 shows the main known 
effects of HIV on osteoblasts and osteoclasts.21
Assessment and diagnosis
The clinical evaluation of patients with suspected osteopo-
rosis should include an overall assessment of their health, 
from physical activities to diseases that secondarily induce 
decreased bone mineral density. The test most recommended 
for diagnosing osteoporosis is measurement of bone mineral 
density (BMD) using DEXA (dual energy X-ray absorpti-
ometry) at two sites, usually the proximal femur and the 
lumbar spine. If these sites cannot be tested for any reason, 
the forearm (radius) is used.22 BMD is calculated through this 
examination by dividing the bone mineral mass (in grams) 
by the surface area of the bones tested (in cm2). The result 
is then compared with two populations:
1.  Young adult population of the same gender. The num-
ber of standard deviations of difference in relation to 
this population is described as the T-score. If the score 
is ,–2.5, a diagnosis of osteoporosis is made, while if it 
is between –2.5 and –1.0, the diagnosis is considered to 
be osteopenia. Findings of $–1.0 are considered to be 
normal BMD.
2.  Population matched according to age and gender. The num-
ber of standard deviations of difference in relation to this 
population is described as the Z-score. Scores of #–2.0 stan-
dard deviations are considered to be abnormal.
T-scores are generally used as the standard for patients 
over the age of 50 years, and Z-scores for those , 50 years 
of age.23 Although the use of the BMD scan for screening 
Table 1 effects of HIV on osteoblasts and osteoclasts
Bone cell Effect Mechanism
Osteoblast ↑ apoptosis TNF-α autocrine/paracrine pathway
↑ activity
↓ differentiation
↓ calcium deposition and ↓  
alkaline phosphatase activity
Deviation to the adipose cell line
Osteoclast ↑ differentiation 
↑ activity
Upregulation of the macrophage  
colony-stimulating factor and RANK-L
Note: Adapted from Borderi M Borderi M, Gibellini D, Vescini F, et al. Metabolic bone 
disease in HIV infection. AIDS. 2009;23(11):1297–1310 with permission of the publisher.21HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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young populations is controversial, this is now a feasible and 
widely available method of diagnosing this disease.
Identifying individuals at risk for osteoporosis helps decide 
whether or not to perform a BMD investigation. Based on 
general population recommendations, a BMD investigation 
should be done upon the occurrence of any of the following:
-	 Women . 65 years;
-	 Men . 70 years;
-	 Postmenopausal women . 50 years with any risk factor 
for fractures;
-	 People with a fracture occurring after 50 years of age;
-	 Prolonged corticosteroid use;
-	 People with conditions inducing loss of bone mass;
-	 People taking medications that induce loss of bone 
mass.24,25
PLWHIV fit in the last two categories at least, and 
therefore should be considered at risk for osteoporosis and 
investigated with DEXA.
The following laboratory tests should be carried out as the 
minimum recommended investigation in cases of osteope-
nia/osteoporosis, to identify secondary causes and to aid in 
scheduling the ideal treatment:24
•	 complete hemogram;
•	 serum calcium and phosphorus;
•	 renal function;
•	 hepatic function;
•	 total protein and fractions;
•	 total cholesterol and fractions;
•	 alkaline phosphatase;
•	 serum vitamin D (1,25 dihydroxyvitamin D);
•	 additional tests depending on the patient: parathormone, 
protein electrophoresis, thyroid-stimulating hormone, 
ertithrocyte sedimentation rate, 24-hour urine for calcium, 
testosterone, or prolactin.
Other tests that could be used include tests for so-called 
bone resorption markers. The most important of these is CTx 
(carboxy-terminal telopeptide of type I collagen). A decrease 
in this marker in the blood can be used as an indicator of 
success in treating osteoporosis, and it is especially useful 
because it presents changes earlier than densitometry. Bone 
formation markers such as osteocalcin, total alkaline phos-
phatase, and N-terminal propeptide of type I procollagen can 
be used in a similar way.25–27
Osteoporosis treatment  
for PLWHIV
For all patients, whether they are HIV-positive or not, 
  osteoporosis treatment has the aims of bone mass   improvement 
and fracture control. Any intervention should also have the 
aims of diminishing pain and physical limitations and 
improving self-esteem and self-confidence, which are the 
main factors responsible for distress among these patients. 
General advice on hygiene and diet, as demonstrated in 
Table 2, should be provided from the outset of the treatment, 
or used as   preventive measures.15
Therapies for treating and preventing osteoporosis began 
with the use of estrogen alone or in combination with a 
progestin. New medications have now appeared, and many 
others are expected to become available in the near future. 
The main types of therapy that currently exist are described 
below.28
Adequate calcium and vitamin D intake
A combination of calcium and vitamin D supplementation 
may reduce the risk of fractures safely and cheaply. Adequate 
calcium intake throughout life is necessary in order to achieve 
peak bone mass and subsequently to maintain bone health. 
The skeleton contains 99% of the body’s calcium deposits. 
When calcium intake is inadequate, bone tissue is reabsorbed 
from the skeleton in order to keep the serum calcium levels 
constant. Calcium intake recommendations are presented in 
Table 3.29 Intake higher than the recommended levels has 
limited benefit and may increase the risk of developing kidney 
stones or cardiovascular disease.30
Current evidence indicates that there is no specific recom-
mendation for calcium supplementation for PLWHIV and 
therefore this population should receive the same age and 
gender recommendations as the general population.
Vitamin D
Vitamin D is fundamental for calcium absorption, bone 
health, muscle performance, balance and reduced risk of 
falls. The recommended vitamin D intake for adults over the 
age of 50 years is 800 to 1000 IU/day, which will maintain 
serum vitamin D at an adequate level of 30 ng/day. In patients 
with osteoporosis the dose of vitamin D should be enough 
to ensure that circulating levels of 1,25 dihydroxyvitamin D 
reach a threshold of 50 nmol/L.31 The main vitamin D-rich 
foods are egg yolk, saltwater fish (salmon, tuna, and   sardines), 
Table  2  General  measures  for  prevention  and  treatment  of 
osteoporosis
Increased calcium intake (milk and derivatives).
Reduced salt, coffee, and alcoholic drink intake.
Optimization of physical activity.
exposure to the sun.
Detection and treatment of the associated disease (AIDS).HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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nuts (eg, walnuts, almonds, hazelnuts, Brazil nuts) and liver. 
Some calcium supplements and most multivitamin pills also 
contain vitamin D. Patients who present with poor absorption 
need higher levels.32,33 When 1,25 dihydroxyvitamin D levels 
are low, cholecalciferol supplementation is required in order 
to normalize these values.
Regular physical activity and quitting smoking are impor-
tant for reducing the risk of fractures, as is reducing excessive 
alcohol consumption (three or more units per day).
Pharmacological treatment
The medications that act on bone metabolism, and form part 
of the therapeutic arsenal against osteoporosis, are classified 
as follows and summarized in Table 4:
•	 Anticatabolic or antiresorptive
•	 Bone-forming or anabolic
•	 Mixed action
Antiresorptive drugs act by blocking osteoclastic activity 
and reducing bone remodeling. On the other hand, bone-
forming drugs stimulate osteoblastogenesis and increase the 
formation of bone matrix. Mixed-action drugs are capable of 
both stimulating bone formation and inhibiting reabsorption. 
Antiresorptive drugs are the group for which the greatest 
quantity of scientific evidence confirming their effectiveness 
for treating osteoporosis exists.34
Anticatabolic or antiresorptive drugs
Hormone therapy
Hormone therapy has been approved by the US Food and 
Drug Administration (FDA) in the United States for osteo-
porosis prevention and for relief of the vasomotor symptoms 
and vulvovaginal atrophy associated with the menopause. 
Studies have shown that women treated with a combination 
of estrogen and progestogen for 5 years presented a 34% 
reduction in the risk of vertebral and hip fracture and a 23% 
reduction in the risk of nonvertebral fractures.35 However, 
neither the FDA nor the European Foundation for Osteopo-
rosis and Bone Disease recommend this therapy as the first 
choice for preventing or treating osteoporosis. Young women 
and postmenopausal women living with HIV require special 
attention because of the associated hormonal changes and 
because of the greater risk of fractures.16
Bisphosphonates
The bisphosphonates most used are alendronate, risedronate, 
ibandronate, and zoledronate. Although all are pyrophosphate 
analogs and reduce bone reabsorption, they differ from each 
other in terms of their mineral affinity and biochemical action 
on bone cells. Clinical studies on bisphosphonates have 
shown different results on the speed with which antifracture 
action begins; their effectiveness at different skeletal sites; 
and the durability and reversibility of their effects. For this 
reason, the documented reductions in vertebral and nonverte-
bral fractures and the indications approved by the FDA differ 
according to the type of bisphosphonate. Several studies are 
in progress with the aim of assessing fracture prevention 
using alendronate and risedronate.
Alendronate: used at a dose of 70 mg/week. This provides 
a 50% reduction in the incidence of vertebral, nonvertebral, 
and femoral fractures in non-HIV-positive osteoporotic 
patients. Although not extensively studied in PLWHIV , Lin 
and Rieder identified 3 open randomized studies show-
ing that alendronate used in association with calcium and 
vitamin D had a beneficial effect on the BMD of osteopenic 
HIV-positive patients for 1 to 2 years, ie, similar to the 
Table 3 Recommended calcium and vitamin D intake29
Life-stage group Calcium  
(mg/day)
Vitamin D   
(IU/day)
Infants 0 to 6 months 200 400
Infants 6 to 12 months 260 400
1 to 3 years old 700 600
4 to 8 years old 1,000 600
9 to 13 years old 1,300 600
14 to 18 years old 1,300 600
19 to 30 years old 1,000 600
31 to 50 years old 1,000 600
51- to 70-year-old males 1,000 600
51- to 70-year-old females 1,200 600
.70 years old 1,200 800
14 to 18 years old,  
Pregnant/Lactating
1,300 600
19 to 50 years old,  
Pregnant/Lactating
1,000 600
Notes: Vitamin D plays an important role in calcium absorption and bone health. It 
is made in the skin after exposure to sunlight and can also be obtained through the 
diet. Although many people are able to obtain enough vitamin D naturally, vitamin 
D production decreases in the elderly, in people who are housebound or do not 
get enough sun, and in some people with chronic neurological or gastrointestinal 
diseases. These individuals and others at risk for vitamin D deficiency may require 
vitamin D supplementation. The recommended daily intake of vitamin D is 400 IU 
for infants; children, and adults up to age 70 should get 600 IU daily. Men and women 
age 70 and older should get 800 IU of vitamin D daily. Reprinted with permission 
from Dietary Reference Intakes for Calcium and Vitamin D, 2011, 2011 by the National 
Academy of Sciences, Courtesy of  National Academies Press, washington, DC.29
Table 4 Medications used in treating osteoporosis, according to 
their active agent
Antiresorptive drugs Bone-forming drugs Mixed-action drugs
Hormone therapy Teriparatide Strontium ranelate
SeRMs
Bisphosphonates
Calcitonin
Abbreviation: SeRMs, selective estrogen receptor modulators.HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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results obtained in studies on postmenopausal osteoporosis.36   
However, these studies only covered 2-year periods and 
the risk of fracture could not be observed. McComsey et al 
showed that in HIV-positive men and women with lower 
BMD, alendronate increased the BMD of the lumbar spine 
and femoral neck when administered with adequate quantities 
of calcium and vitamin D, and that adverse gastrointestinal 
events were well tolerated.37
Risedronate: used at a dose of 35 mg/week. Recently, rise-
dronate administered once a month (150 mg) was approved. A 
comparative study between risedronate 5 mg/day and 150 mg/
month demonstrated that the monthly dose was comparable 
with the daily dose in terms of safety and efficacy for treating 
postmenopausal women with osteoporosis. It has been shown 
to reduce the incidence of vertebral, nonvertebral, and femo-
ral fractures by 50%. Its action is rapid and takes place after 
6 months of use.38 For this reason, it can be recommended 
for patients who are at a high risk of new fractures. In addi-
tion to indications for prevention and treatment of vertebral 
and nonvertebral fractures in postmenopausal women; rise-
dronate is also indicated for treating male osteoporosis and 
for maintaining and increasing the bone mass of patients 
who are using systemic corticoids. The particular features 
of this bisphosphonate indicate that this drug starts to act 
quickly and is an option for all patients, including HIV-
positive individuals despite the lack of specific evidence for 
this population.
Zoledronate: Used at a dose of 5 mg, with intravenous 
infusion over a 15-minute period once a year, zoledronate 
has been found to reduce the incidence of vertebral fractures 
by 70% and hip fractures by 40%, in patients with osteopo-
rosis, but not specifically among HIV-positive individuals. 
It has also been found to reduce the risks of fractures and 
mortality when administered a few days after the first hip 
fracture. The side effects are similar to those of all other oral 
bisphosphonates, with the advantage that it does not cause 
gastrointestinal problems, inflammation of the esophagus, or 
peptic ulcers. There have been reports of osteonecrosis of the 
mandible, especially in cancer patients who are using intra-
venous bisphosphonates. Patients should receive high doses 
of vitamin D and calcium before receiving zoledronate, in 
order to reduce the possibility of developing hypocalcemia. 
Bolland et al showed that an annual infusion of zoledronate 
was effective in terms of densitometry results among 
osteopenic HIV-positive men.39 Another small clinical trial 
confirmed these findings in HIV-positive men and women, 
and also showed reduction in bone resorption markers in the 
zoledronate group.40
Bone-forming or anabolic drugs
Teriparatide (PTH)
This drug has been approved for postmenopausal osteo-
porosis treatment among women who are at high risk of 
developing fractures, and it should be administered daily by 
means of subcutaneous injection. PTH at a dose of 20 micro-
grams/day reduces the risk of vertebral fractures by 65% and 
nonvertebral fractures by 53%, among patients treated for 
18 months.41 No data are available on its efficacy and safety 
when used for longer periods, and there are few reports on 
HIV-positive patients.
Mixed-action drugs
Strontium ranelate
Strontium is incorporated into the bone and seems to have 
double action on bone tissue: it stimulates formation and 
reduces reabsorption. In patients with osteoporosis, strontium 
ranelate produces increased levels of biochemical markers 
for bone formation and decreased levels of the markers for 
reabsorption. It increases bone density by 14.4% in the lum-
bar spine and by 8.3% in the femoral neck.42 There are no 
studies on this drug among HIV-positive patients.
Denosumab
Denosumab is a human monoclonal antibody, recently been 
approved by the FDA. It acts by inhibiting the action of 
RANK-L, thereby inhibiting the action of osteoclasts, their 
differentiation, and survival. In a recent study among men 
with prostate cancer and androgen deprivation, there was a 
5.6% increase in bone mass and a decrease in the incidence 
of fractures over a 36-month period.43–46 There are no studies 
on HIV-positive patients, but these findings suggest that it 
may be possible to use this drug to treat HIV-related bone 
mass losses. However, the immunological consequences of 
inhibiting RANK in HIV-positive patients are unknown and 
should be studied.
In summary, the only drugs with adequately designed 
studies for HIV-positive population are alendronate and zole-
dronate, apparently with similar results as previous studies 
for the general osteoporotic population. Studies with other 
drugs are currently in progress. FDA Advisory   Committee 
Reviews Prolia Thousand Oaks, California, August 13/
PRNewswire-FirstCall/–Amgen Inc issued the following 
statement on the outcome of today’s meeting with the US 
Food and Drug Administration (FDA) Advisory Committee 
for Reproductive Health Drugs (ACRHD) to review the 
potential use of Prolia (denosumab) for the prevention and 
treatment of postmenopausal osteoporosis and the prevention HIV/AIDS - Research and Palliative Care 2011:3 submit your manuscript | www.dovepress.com
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and treatment of bone loss in patients undergoing hormone 
ablation for either prostate cancer or breast cancer. FDA 
recommended and approved.
Finally, the panel recommended that Prolia have a Risk 
Evaluation and Mitigation Strategy (REMS), which could 
include a medication guide and a healthcare provider com-
munications plan.
Often referred to as the “silent   epidemic,” osteoporosis 
is a global problem that is increasing in significance as the 
population of the world both increases and ages.
Nondrug intervention
Rigorous, prolonged adherence to HAART increases the 
survival of PLWHIV , but does not exempt them from a variety 
of complications, such as osteoporosis or osteopenia.46–48
Despite the real risk, osteoporosis-related fractures in 
PLWHIV remain little reported. It has been estimated that 
this will become a public health problem if measures are 
not taken.49,50
Physical activity is a health promotion strategy for the 
general population, but only preliminary data on its real 
value and benefit among PLWHIV is available, especially 
in relation to osteoporosis.51,52
The literature increasingly shows evidence that regular 
physical activity of light to moderate intensity is safe and 
reduces pain, incapacity, and cardiovascular risk in the 1 
population.53,54
Physical activity has also been correlated with improved 
quality of life, functional independence, aerobic capacity, and 
positive psychological changes. It is effective for preventing 
and treating osteoporosis and falls.55
There is no consensus on the role of exercise among 
PLWHIV with osteoporosis. Given that cardiovascular dis-
ease is a frequent cause of general mortality, a small increase 
in cardiac risk would significantly increase the morbidity-
mortality in the HIV-infected subgroup. Physical activity is 
indicated at least with the aim of minimizing the cardiac risk 
among PLWHIV .51
Impact, weight offloading, muscle strengthening,   balance, 
and coordination exercises that are performed regularly have 
been shown to provide benefits for   individuals with osteoporo-
sis and osteopenia, through improving their performance and 
functionality in day-to-day activities, improving their BMD in 
the spine and hips and reducing their risk of falling.51,52
Other physical interventions include the use of vibra-
tory platforms, functional electrical stimulation, laser, and 
ultrasound. However, even though the data show that these 
interventions have some benefit, they cannot be used as 
the only therapy or to the detriment of drug interventions 
or physical activity. These interventions may be useful for 
individuals with limitations or with contraindications for the 
current habitual treatments.56
Treating osteoporosis has the ultimate aim of   preventing 
serious fractures such as in the hip and spine. Other interven-
tions that diminish the risk of falls are also important. In this 
respect, adaptation of the environment through installation of 
adequate lighting, handrails, safety barriers, and appropriate 
flooring has become more prominent, as well as the use of 
orthoses and walking aids such as special footwear, walk-
ing sticks, walking frames, and crutches, which increase the 
individual’s support base, sustainment, and proprioception.
Although PLWHIV are usually younger than the general 
population with osteoporosis and therefore less prone to 
falls, this population is growing older, and together with 
HIV-related conditions as lipodystrophy and hypogonad-
ism, which induce muscle mass loss, prevention of falls 
cannot be neglected. Besides, PLWHIV are much more 
active and are exposed to traumas, unlike the elderly 
population.
While science seeks to identify the best way of managing 
osteoporosis among PLWHIV , these individuals continue to 
live and need rapid answers to ensure that their plans for life 
can continue with as little interference as possible from any 
comorbidities and complications from dysfunctional bone 
tissue that may be present. Despite the lack of specific data, 
the requirements of PLWHIV cannot go unmet and without 
guidance. Physical activity can be recommended as a safe 
and biologically plausible intervention for preventing falls 
and for improving BMD and bone quality.
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